Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. The salvage pathway becomes upregulated during autoimmune diseases. FDA approved drugs blocking the de novo pathway include Aubagio (teriflunomide), Mavenclad (cladribine), and CellCept (mycophenolate mofetil).
Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. The salvage pathway becomes upregulated during autoimmune diseases. FDA approved drugs blocking the de novo pathway include Aubagio (teriflunomide), Mavenclad (cladribine), and CellCept (mycophenolate mofetil).